Drug Trial Radar · NCT04166058
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
381
Actual
Start
Nov 19, 2019
Primary completion
Jun 5, 2025
Study completion Jun 5, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- First posted
- Nov 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants (6-17 years of age) with FC or IBS-C who completed study intervention in studies LIN-MD-62, LIN-MD-63, or LIN-MD-64 based on the individual study criteria.
Conditions
- Irritable Bowel Syndrome With Constipation
- Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)Drug
Participants who completed study LIN-MD-63 at their time of enrollment will be assigned a dose of 290 μg. Participants who received ≤ 145 μg linaclotide or placebo in study LIN-MD-63 at the time of completion will continue to receive 145 μg. Participants who completed study LIN-MD-64 at their time of enrollment will be assigned a dose of 290 μg if they choose to receive open-label or continue to receive blinded dose of 145 or 290 μg if they choose to remain on the same blinded dose.
Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)Drug
Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Participants whom are between the ages of 12-17 years old at their time of enrollment will be randomized at 1:1 ratio to 72 or 145 μg linaclotide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs).Time frame: From first dose of study drug until 30 days following last dose of study drug [up to 24 weeks (FC participants) or 52 weeks (IBS-C participants)].
Locations
72 sites in 4 countries. Site status is shown where the registry gives one.
Central Research Associates /ID# 237953
Birmingham, Alabama
G & L Research, LLC /ID# 238093
Foley, Alabama
The Center for Clinical Trials Inc. /ID# 234605
Saraland, Alabama
HealthStar Research of Hot Springs PLLC /ID# 234608
Hot Springs, Arkansas
Preferred Research Partners /ID# 237109
Little Rock, Arkansas
Applied Research Center of Arkansas /ID# 238069
Little Rock, Arkansas
Advanced Research Center /ID# 237960
Anaheim, California
Kindred Medical Institute, LLC /ID# 237367
Corona, California
Duplicate_Center for Clinical Trials LLC /ID# 234629
Paramount, California
Medical Ctr for Clin Research /ID# 236911
San Diego, California
Lynn Institute of Denver /ID# 238086
Aurora, Colorado
Childrens National Medical Center /ID# 234417
Washington D.C., District of Columbia
Prohealth Research Center /ID# 234659
Doral, Florida
Dolphin Medical Research /ID# 234676
Doral, Florida
Amedica Research Institute Inc /ID# 234666
Hialeah, Florida
Nemours Childrens Specialty Care /ID# 237991
Jacksonville, Florida
Elite Clinical Research /ID# 234651
Miami, Florida
My Preferred Research LLC /ID# 237943
Miami, Florida
South Miami Medical & Research Group Inc. /ID# 234654
Miami, Florida
Valencia Medical & Research Center /ID# 234671
Miami, Florida
Advanced Research for Health Improvement /ID# 238253
Naples, Florida
Pediatric & Adult Research Center /ID# 234681
Orlando, Florida
Nemours Children's Hospital /ID# 234429
Orlando, Florida
Oviedo Medical Research /ID# 234692
Oviedo, Florida
Treken Primary Care /ID# 234645
Atlanta, Georgia
Children's Healthcare of Atlanta - Ferry Rd /ID# 237005
Atlanta, Georgia
Children's Ctr Digestive, US /ID# 237574
Atlanta, Georgia
River Birch Research Alliance /ID# 237963
Blue Ridge, Georgia
Clinical Research Institute /ID# 234702
Stockbridge, Georgia
Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 236342
Stockbridge, Georgia
KU Wichita Center for Clinical Research /ID# 234500
Wichita, Kansas
Michael W. Simon, MD, PSC /ID# 236516
Lexington, Kentucky
Virgo Carter Pediatrics /ID# 234518
Silver Spring, Maryland
MNGI Digestive Health, P. A. /ID# 234437
Minneapolis, Minnesota
GI associates and Endoscopy Ce /ID# 237969
Flowood, Mississippi
David M. Headley, MD, P.A. /ID# 238216
Port Gibson, Mississippi
Private Practice - Dr. Craig Spiegel /ID# 234545
Bridgeton, Missouri
Medclinical Research Partners LLC/ Foundation Pediatrics /ID# 234566
East Orange, New Jersey
University of New Mexico /ID# 236983
Albuquerque, New Mexico
Columbia University Irving Medical Center /ID# 235686
New York, New York
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.